STAAR Surgical Reports Strong Q2 Earnings Driven by Growth in China and Americas
STAAR Surgical (STAA) reported a record $93.5 million in net sales for Q2 2026, marking an 111% year-over-year increase driven primarily by strong performance in the Chinese market and continued growth in the Americas. Revenue from China reached $52.3 million, up over 100% annually due to the successful launch of EVO Plus, which now accounts for about one-third of units sold there. The U.S. saw stable net sales at $6.0 million as it gained market share from laser vision correction procedures. The company returned to profitability with a net income of $8.1 million or $0.16 per diluted share and reported adjusted EBITDA of $20.0 million, reversing a loss in the same period last year. Gross margin improved slightly to 74.5%, aided by reduced manufacturing costs and inventory provisions. Management also highlighted strong cash reserves at quarter-end totaling $181.5 million. Looking ahead, STAAR expects continued growth with plans for strategic investments while maintaining focus on innovation and expanding its product portfolio beyond a single-product model.
Tickers: $STAA
Topics: adjusted_ebitda financial_performance net_income revenue_growth